Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573931 | 1.00 | GPR119 (0.48) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL5576545 | 0.91 | GPR119 (0.47) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4597797 | 0.91 | GPR119 (0.47) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4597577 | 0.89 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL5576335 | 0.89 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4609959 | 0.89 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4609951 | 0.89 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4609430 | 0.89 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4609424 | 0.89 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL5573696 | 0.88 | GPR119 (0.45) | GPR119KDM4EMAPTTHRBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | GPR119 229/4885KDM4E 3689/4885MAPT 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.